%PDF-1.4
%
120 0 obj
<>
endobj
117 0 obj
<>
endobj
176 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T16:16:21Z
2024-03-29T00:54:19-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T00:54:19-07:00
application/pdf
Heather
2001-585.july02
uuid:abc18c67-1dd1-11b2-0a00-c30827bd7700
uuid:abc18c6a-1dd1-11b2-0a00-900000000000
endstream
endobj
106 0 obj
<>
endobj
107 0 obj
<>
endobj
121 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
35 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
58 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
81 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
94 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
206 0 obj
[210 0 R]
endobj
207 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 70.6667 714.5293 Tm
(osteoarthritis. Br J Rheumatol 1992;31:605-8.)Tj
-0.00011 Tc -1.1667 -1.25 Td
[(7.)-416.8 (Mollenhauer J, von der Mark K, Burmester G, et al. Serum)]TJ
0 Tc 1.1667 -1.25 Td
(antibodies against chondrocyte cell surface proteins in osteoarthritis)Tj
0 -1.25 TD
[(and rheumatoid arthritis. J Rheumatol 1988;15:181)36.9 (1-7.)]TJ
-0.00011 Tc -1.1667 -1.25 Td
[(8.)-416.8 (Doherty M, Patrick M, Powell RJ. Hypothesis \227 nodal generalized)]TJ
0 Tc 1.1667 -1.25 Td
[(osteoarthritis is an autoimmune disease. )54.8 (Ann Rheum Dis)]TJ
0 Tw T*
(1990;49:1017-20.)Tj
0.02499 Tw -1.1667 -1.25 Td
[(9.)-416.7 (Shuckett R, Russel ML, Gladman DD. )54.9 (A)-219.8 (typical erosive)]TJ
-0.0051 Tc 1.1667 -1.25 Td
[(osteoarthritis and Sjogren syndrome. )54.7 (Ann Rheum Dis 1986;45:281-8.)]TJ
0 Tc -1.6667 -1.25 Td
[(10.)-416.7 (Stamenkovic I, Stegagno M, )17.8 (W)39.8 (right KA, et al. Clonal dominance)]TJ
-0.00011 Tc 1.6667 -1.25 Td
[(among )17.7 (T)91.7 (-lymphocyte infiltrates in arthritis. Proc Natl )54.8 (Acad Sci USA)]TJ
0 Tc 0 Tw T*
[(1988;85:1)36.9 (179-83.)]TJ
0.0249 Tw -1.6298 -1.25 Td
[(1)36.9 (1.)-416.7 (Nakamura H, )36.8 (Y)100.1 (osino S, )17.7 (T)69.8 (suruha J, et al. )17.7 (T)91.8 (-cell mediated)]TJ
1.6298 -1.25 Td
(inflammatory pathway in osteoarthritis. Osteoarthritis Cartilage)Tj
0 Tw T*
(1999;7:401-2.)Tj
0.0249 Tw -1.6667 -1.25 Td
[(12.)-416.7 (Charriere G, Hartmann DJ, )17.7 (V)60.1 (ignon E, Ronziere M-C, Herbage D,)]TJ
-0.00011 Tc 1.6667 -1.25 Td
[(V)60 (ille G. )54.8 (Antibodies to )17.7 (T)69.7 (ypes I, II, IX, and XI collagen in the serum)]TJ
-0.005 Tc T*
[(of patients with rheumatic diseases. )54.8 (Arthritis Rheum 1988;31:325-32.)]TJ
0 Tc -1.6667 -1.25 Td
[(13.)-416.7 (Poll )54.8 (AR. Immunology of cartilage. In: Moskowitz R)54.9 (W)91.8 (, Howell DS,)]TJ
-0.00011 Tc 1.6667 -1.25 Td
[(Goldber)17.7 (g )17.7 (VM, Mankin HJ, editors. Osteoarthritis diagnosis and)]TJ
0 Tc T*
[(medical/sur)17.8 (gical management. 2nd ed. Philadelphia: )17.7 (WB Saunders;)]TJ
0 Tw T*
(1992:155-89.)Tj
0.0249 Tw -1.6667 -1.25 Td
[(14.)-416.7 (Golds EE, Cooke )17.7 (TD, Poole )54.8 (AR. Immune regulation of collagenase)]TJ
1.6667 -1.25 Td
(secretion in rheumatoid and osteoarthritic synovial cell cultures. Coll)Tj
T*
(Relat Res 1983;3:125-40.)Tj
-1.6667 -1.25 Td
[(15.)-416.7 (Neame PJ, Christner JE, Baker JR. Cartilage proteoglycan)]TJ
1.6667 -1.25 Td
(aggregates: the link protein and proteoglycan amino-terminal)Tj
T*
(globular domains have similar structures. J Biol Chem)Tj
0 Tw T*
(1987;262:17768-78.)Tj
-0.00011 Tc 0.02499 Tw -1.6667 -1.25 Td
[(16.)-416.8 (Barry FP)110.8 (, Rosenber)17.7 (g LC, Gaw JU, Koob )17.7 (TJ, Neame PJ. N- and )]TJ
0 Tc 1.6667 -1.25 Td
(O-linked keratan sulfate on the hyaluronan binding region of)Tj
T*
(aggrecan from mature and immature bovine cartilage. J Biol Chem)Tj
0 Tw T*
(1995;270:20516-24.)Tj
-0.00011 Tc 0.02499 Tw -1.6667 -1.25 Td
[(17.)-416.8 (Heinegard D, )54.8 (Axelsson I. Distribution of keratan sulfate in cartilage)]TJ
0 Tc 1.6667 -1.25 Td
(proteoglycans. J Biol Chem 1977;252:1971-9.)Tj
-1.6667 -1.25 Td
[(18.)-416.7 (Fosang )54.8 (AJ, Hardingham )17.7 (TE. Isolation of the N-terminal globular)]TJ
1.6667 -1.25 Td
(protein domains from cartilage proteoglycans: identification of G2)Tj
T*
(domain and its lack of interaction with hyaluronate and link protein.)Tj
T*
(Biochem J 1989;261:801-9.)Tj
-0.00011 Tc -1.6667 -1.25 Td
[(19.)-416.8 (Glant )17.7 (TT)73.9 (, Mikecz K, )17.7 (Thonar EJM, Kuettner KE. Immune responses)]TJ
0 Tc 1.6667 -1.25 Td
(to cartilage proteoglycans in inflammatory animal models and)Tj
-0.00011 Tc T*
[(human disease. In: )17.7 (W)79.7 (oessner JF Jr)39.7 (, Howell DS, editors. Joint)]TJ
0 Tc T*
[(cartilage degradation: basic and clinical aspects. New )36.8 (Y)100.1 (ork: Marcel)]TJ
T*
(Dekker; 1993:435-73.)Tj
-0.00011 Tc -1.6667 -1.25 Td
[(20.)-416.8 (Karopoulos C, Rowley MJ, Ilic MZ, Handley CJ. Presence of )]TJ
0 Tc 1.6667 -1.25 Td
(antibodies to native G1 domain of aggrecan core protein in synovial)Tj
-0.00011 Tc T*
[(fluids from patients with various joint diseases. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1996;39:1990-7.)Tj
0.02499 Tw -1.6667 -1.25 Td
[(21.)-416.7 (Guerassimov )54.9 (A, Zhang )36.9 (Y)129.2 (, Banerjee S, et al. )54.9 (Autoimmunity to)]TJ
1.6667 -1.25 Td
(cartilage link protein in patients with rheumatoid arthritis and)Tj
T*
(ankylosing spondylitis. J Rheumatol 1998;25:1480-4.)Tj
-0.00011 Tc 31.3333 62.5 Td
[(22.)-416.8 (Bari )54.8 (AS, Carter SD, Bell SC, Mor)17.7 (gan K, Bennet D. )54.8 (Anti-type II)]TJ
0 Tc 1.6667 -1.25 Td
(collagen antibody in naturally occurring canine joint diseases. Br J)Tj
T*
(Rheumatol 1989;28:480-6.)Tj
-1.6667 -1.25 Td
[(23.)-416.7 (V)111.1 (erheijden GFM, Rijnders )54.8 (A)80.1 (WM, Bos E, et al. Human cartilage)]TJ
1.6667 -1.25 Td
(glycoprotein-39 as a candidate antigen in rheumatoid arthritis.)Tj
T*
[(Arthritis Rheum 1997;40:1)36.9 (1)36.9 (15-25.)]TJ
-0.00011 Tc -1.6667 -1.25 Td
[(24.)-416.8 (Johansen JS, Stoltenber)17.7 (g M, Hansen M, et al. Serum )36.7 (YKL-40 )]TJ
0 Tc 1.6667 -1.25 Td
(concentrations in patients with rheumatoid arthritis: relation to)Tj
T*
[(disease activity)64.9 (. Rheumatology 1999;38:618-26.)]TJ
-0.00011 Tc -1.6667 -1.25 Td
[(25.)-416.8 (V)129.1 (olck B, Oster)17.7 (gaard K, Johansen JS, Garbausch C, Price P)91.7 (A. )17.7 (The)]TJ
0 Tc 1.6667 -1.25 Td
[(distribution of )36.9 (YKL-40 in osteoarthritic and normal human cartilage.)]TJ
T*
(Scand J Rheumatol 1999;28:171-9.)Tj
-1.6667 -1.25 Td
[(26.)-416.7 (Hu B, )17.7 (T)34.9 (rich K, Fignenia )17.7 (WF)79.8 (, Prince P)91.8 (A. Isolation and sequence of a)]TJ
1.6667 -1.25 Td
(novel human chondrocyte protein related to mammalian members of)Tj
T*
[(chitinase protein family)64.9 (. J Biol Chem 1996;271:19415-20.)]TJ
-1.6667 -1.25 Td
[(27.)-416.7 (Sekine )17.7 (T)74 (,)0.1 ( Masuko-Hongo K, Matsui )17.7 (T)74 (, et al. )36.8 (YKL-39, a human )]TJ
1.6667 -1.25 Td
[(cartilage-related protein, is recognized as a tar)17.8 (get antigen in patients)]TJ
T*
[(with rheumatoid arthritis. )54.9 (Ann Rheum Dis 2001;60:49-54.)]TJ
-1.6667 -1.25 Td
[(28.)-416.7 (Altman RD. )17.8 (The classification of osteoarthritis. J Rheumatol)]TJ
1.6667 -1.25 Td
(1995;22 Suppl 43:42-3.)Tj
-0.00011 Tc -1.6667 -1.25 Td
[(29.)-416.8 (Kellgren JH, Lawrence JS. Radiological assessment of osteoarthritis.)]TJ
0 Tc 1.6667 -1.25 Td
(Ann Rheum Dis 1957;16:494-501.)Tj
-0.00011 Tc -1.6667 -1.25 Td
[(30.)-416.8 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.6667 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
0 Tc T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-1.6667 -1.25 Td
[(31.)-416.7 (Y)100.1 (oichi O, )36.8 (Y)111.1 (uso G, )36.8 (Y)111.1 (usuke K, et al. Purification of an angiogenesis)]TJ
1.6667 -1.25 Td
(inhibitor from culture medium conditioned by human )Tj
T*
(chondrosarcoma-derived chondrocytic cell lines HCS-2/8. Biochem)Tj
-0.02991 Tw T*
[(Biophys Acta )-54.9 (1995;1245:1-8.)]TJ
0.0249 Tw -1.6667 -1.25 Td
[(32.)-416.7 (Matsui )17.7 (T)74 (,)0.1 ( Kurokawa M, Kobata )17.7 (T)74 (, et al. )54.8 (Autoantibodies to )17.7 (T)-257.2 (cell)]TJ
1.6667 -1.25 Td
(costimulatory molecules in systemic autoimmune diseases. )Tj
T*
(J Immunol 1999;162:4328-35.)Tj
-1.6667 -1.25 Td
[(33.)-416.7 (Y)100.1 (amamoto K, Miura H, Moroi )36.8 (Y)129.2 (, et al. Isolation and characterization)]TJ
1.6667 -1.25 Td
[(of a complementary DNA)-220.1 (expressing human U1 small nuclear )]TJ
T*
[(ribonucleoprotein C polypeptide. J Immunol 1988;140:31)36.9 (1-7.)]TJ
-0.00011 Tc -1.6667 -1.25 Td
[(34.)-416.8 (Guerassimov )54.8 (A, Zhang )36.8 (Y)129.1 (,)-0.1 ( Cartman )54.8 (A, et al. Immune responses to)]TJ
0 Tc 1.6667 -1.25 Td
(cartilage link protein and the G1 domain of proteoglycan aggrecan in)Tj
T*
[(patients with osteoarthritis. )54.8 (Arthritis Rheum 1999;42:527-33.)]TJ
-1.6667 -1.25 Td
[(35.)-416.7 (Lohmander LS, Saxne )17.7 (T)74 (, Heinegard DK. Release of cartilage)]TJ
1.6667 -1.25 Td
(oligomeric matrix protein \(COMP\) into joint fluid after knee injury)Tj
T*
[(and in osteoarthritis. )54.9 (Ann Rheum Dis 1994;53:8-13.)]TJ
-0.00011 Tc -1.6667 -1.25 Td
[(36.)-416.8 (Lorenzo P)110.7 (, Bayliss M, Heinegard D. )54.8 (A)-219.9 (novel cartilage protein)]TJ
0 Tc 1.6667 -1.25 Td
(\(CILP\) present in the mid-zone of human articular cartilage)Tj
T*
(increases with age. J Biol Chem 1998;36:23463-8.)Tj
-0.00011 Tc -1.6667 -1.25 Td
[(37.)-416.8 (T)69.7 (suruha J, Masuko-Hongo K, Kato )17.7 (T)73.9 (, Sakata M, Nakamura H,)]TJ
0 Tc 1.6667 -1.25 Td
(Nishioka K. Implication of cartilage intermediate layer protein)Tj
-0.00011 Tc T*
(\(CILP\) in cartilage destruction in subsets of patients with)Tj
0 Tc T*
[(osteoarthritis and rheumatoid arthritis. )54.8 (Arthritis Rheum 2001;)]TJ
0 Tw T*
(44:838-45.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:7)Tj
0 Tw -46.2952 -0.0313 Td
(1466)Tj
ET
0 0 0 0 scn
/GS0 gs
103.25 59.08 407.5 -10.83 re
f*
0.5 w
103.25 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
159 0 obj
<>
endobj
181 0 obj
<>
endobj
130 0 obj
<>
endobj
123 0 obj
<>
endobj
125 0 obj
<>
endobj
153 0 obj
<>stream
HV p}3@Ё KZCZ K$̱d@ @% #PQر"X 3bKe
,e@qavf%UL] mPyc^0.W.=WWgv-K@_V9b¡(Y˶|aזKv^ml>D
O8Z^Qs'WYs\hLjdAeD||~P.3ʺM
*yQ꘨Ue?kT [VP˄;XkKI?qo `1KQnHEP+،8b=v'h/6"Ts}
\_8KG:4z-CT`9Y zo![MVA^O:h8c!:X0DI>ݑǝs>.sy\`a
6!SdRge[Zq}
YdypOQVWk`$tAA1跞slWpUDb+[8#[YUZ.gM*Y sxuxwD*2E*䳲LΑ7VXCL$+`&{`d+`^Aw2ہ8\DЄCn"_ /%c!ʋJ2XRhwVUd͵>b0K{52UxOn;½O4sIMxd)l"-Yj+Q#b9Acd,bJ~,O3KyMޔ?(JbDuMi5>o'ÊRjkŪgU
e2mIcUGb4[OdLC10Ylnd>73ug;ŪUF!Be;<(PLSTQ&\XW1ʭb#ⶸj2RLgereB.+MI#?KSǙePiD)J_62R:e]٩|TC塚fcEA۷Z;-Ch%Lm괽y~X0a8Ku|~G4g3ޗҋK,#Oü}r8Ɠ5b7bxIm8e#kX Pރ[g>:հF4!Fd =g